Classifications

• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K9/00—Medicinal preparations characterised by special physical form
  • A61K9/0012—Galenical forms characterised by the site of application
  • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
  • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K9/00—Medicinal preparations characterised by special physical form
  • A61K9/20—Pills, tablets, discs, rods
  • A61K9/2004—Excipients; Inactive ingredients
  • A61K9/2013—Organic compounds, e.g. phospholipids, fats
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K9/00—Medicinal preparations characterised by special physical form
  • A61K9/20—Pills, tablets, discs, rods
  • A61K9/2004—Excipients; Inactive ingredients
  • A61K9/2022—Organic macromolecular compounds
  • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K9/00—Medicinal preparations characterised by special physical form
  • A61K9/20—Pills, tablets, discs, rods
  • A61K9/2004—Excipients; Inactive ingredients
  • A61K9/2022—Organic macromolecular compounds
  • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
  • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose

Definitions

• the present invention is directed to an oral disintegratable tablet which exhibits oral disintegratability of not more than 60 seconds.
• the tablet for oral administration comprises an effective amount of at least one active agent, an amount of at least 50% (w/w) of a water insoluble parts, a surfactant and a disintegrant, such that said tablet is orally disintegretable or dispersable.
• Oral dispersable tablets are in principle not different from common immediate release (IR) tablets. They should be mechanically stable, to allow handling during technical operations and handling by the patient or customer. Their disintegration time in aqueous environment should be fast and complete. A softening under the conditions of release, so that weak mechanical stress is sufficient for complete dispersion, is also acceptable.
• IR immediate release
• tablets containing gas-developing mixtures of at least one acid component (like e.g. citric acid) and at least one basic component in form of a carbonate or hydrogen-carbonate are described e.g. in US 2002/01 10578.
• Another common method is the use of rapidly soluble tablet excipients like e.g. sugar alcohols (Mannitol, Sorbitol, Xylitol, Erythritol etc.), sugars or specialized forms of these like PharmaburstTM or F-MeltTM. Rapid disintegration is a result of the dissolution of these excipients.
• Another difficulty in the rapid disintegration in the oral cavity is the limited amount of liquid that is present.
• the liquid inside the oral cavity is of higher viscosity.
• the amount of liquid and its viscosity is not constant.
• the amount of liquid consumed smoking-status
• Highly porous tablet structures, into which liquid can easily penetrate are therefore also common in the field of oral dispersable tablets.
• Several specialized manufacturing technologies ensure highly porous tablet structures.
• the geometry of the tablet can also influence the disintegration time. Short ways for liquid penetration are preferred. This prerequisite also influences the tablet shape and geometry.
• the desired optimal geometry also has to consider mechanical stability, as described already.
• the costs are important.
• the manufacturing cost should be as low as possible. This can best be achieved by using established standard technologies and keeping the manufacturing process as lean as possible. Any additional manufacturing step would increase cost and has to be avoided. Also the use of specialized excipients tends to increase the costs, as these are more expensive than standard excipients.
• the target group for the application of oral dispersable tablets can be found in patients with difficulties in swallowing tablets or in groups were water for the intake of normal tablets is not readily available. In some markets the convenience of taking tablets without water has a high preference. In all cases, the disintegration time of the tablet should be short and the patient/costumer should get the impression of something happening with the tablet inside his mouth. This perception of disintegrating action helps the patients/costumers expectation of a positive influence of the active principle(s) on his/her state or health.
• JP 9071523 describes the formulation of oral dispersable tablet.
• MCC microcrystalline cellulose
• L-HPC low substituted hydroxyl-propyl Cellulose
• WO 2004091585 describes the use of Prosolv (silicified microcrystalline Cellulose) for the formulation of oral dispersable tablets.
• Prosolv is a trademark excipient and further described in the US 6471994 as a new tablet excipient also for the use with oral dispersable tablets.
• surfactants and hydrophilic, wetting polymers like Poloxamer, are used to aid the wettability of active ingredients (drug substance(s)) or increase their bioavailibilty by enhancing their dissolution.
• surfactants can be used to reduce the viscosity of the aqueous media inside the oral cavity, independent of the wettability of the active. This effect can be promoted by the use of one or more sweet tasting substances inside the formulation. Salt (NaCl), acid components or intensive flavour can have a similar effect and would also reduce the viscosity of the aqueous media inside the oral cavity.
• the present invention is directed to a non-effervescent tablet for oral administration, comprising an effective amount of at least one active agent, an amount of at least 50% (w/w) of a water insoluble parts, a surfactant and a disintegrant, such that said tablet is orally disintegretable or dispersable
• the said tablet exhibits oral disintegratabihty in not more than 60 seconds
• the tablet exhibits oral disintegratabihty in not more than 30 seconds
• the tablet exhibits oral disintegratabihty in not less than 5 seconds
• Most preferred the tablet exhibits oral disintegratabihty in not less than 2 seconds
• the water insoluble carrier in the tablet is selected from the group Cellulose, microcrystalline Cellulose or sihcified microcrystalline Cellulose or mixtures thereof
• the sihcified microcrystalline cellulose is contained in an amount within the range of 20% to 90% preferably within the range of 25% to 60%
• the said sihcified microcrystalline cellulose contains 1 -5% silicon dioxide
• the tablet sihcified microcrystalline cellulose in the tablet has an average particle size within the range of 20-300 ⁇ m
• the desintegrant in the tablet is selected from the group consisting of low substituted hydroxypropyl cellulose, carboxymethyl cellulose, crosscarmelose sodium, crosspovidone (crosslinked Polyvinylpyrohdone), sodium starch glycolate, starch, and combinations thereof
• Preferrabihty the disintegrant is low substituted hydroxypropyl cellulose or crosspovidone (crosslinked Polyvinylpyrohdone) or combinations thereof
• the disintegrant is contained in the tablet in an amount of 0 5% to 50%
• the surfactant in the tablet is selected from the group Sodium dodecylsulfate, Polyoxyethylen Sorbitan fatty acid esters (Tweens), Polyoxyethylene Stearates, Sorbitan fatty acid esters (Spans)
• the tablet according to the invention has a friability of less than 1 %
• the tablet according to the invention does not contain a water soluble binder
• the tablet according to to the invention may further comprises at least one additional excipient selected from the group consisting of taste masking agents, sweeteners, lubricants, stabilizers, preservatives, and pH-adjustors
• the active agent in the tablet according to the invention is selected from the group consisting of pharmaceutical active agents, nutrients, nut ⁇ ceuticals, and cosmetics
• the active agent can be one or more vitamins
• the active agent can also be one or more pharmaceutically active agent(s)
• the said pharmaceutically active agent can be present in the form of coated particles containing said pharmaceutically active agent
• the coating can be an extended release or an enteric coating
• the tablet according to the invention is a tablet, wherein said pharmaceutically active agent is selected from the group consisting of antiinflammatories, antirheumatics, antiemetics, analgetics, antiepileptics, antipsychotics, antidepressants, hypnotics, antiulce ⁇ cs, prokinetic, antiasthmatics, antiparkinsonics, cardiovasculars, vasodilators, urologies, hypolipidemics, antidiabetics, and antihistamines
• said pharmaceutically active agent is selected from the group consisting of antiinflammatories, antirheumatics, antiemetics, analgetics, antiepileptics, antipsychotics, antidepressants, hypnotics, antiulce ⁇ cs, prokinetic, antiasthmatics, antiparkinsonics, cardiovasculars, vasodilators, urologies, hypolipidemics, antidiabetics, and antihistamines
• the said pharmaceutically active agent can be selected from the group consisting of lbuprofen, acetominophen, piroxicam, leflunomide, ondansetron, granisetron, paracetamol, carbamazepin, lamot ⁇ gine, clozapine, olanzapine, risperidone, citalopram, paroxetine, sertraline, fluoxetine, fluvoxamine, zopiclon, Zolpidem, cimetidine, ranitidine, omeprazole, metoclopramide, cisapride, dompe ⁇ don, zafirlukast, montelukast, prarnipexol, selegiline, Zolpidem, zopiclon, doxazosin, terazosin, atenolol, bisoprolol, amlodipme, nifedipine, diltiazem, enalap ⁇ l, cap
• the pharmaceutical orally disintegratable non-effervescent tablet is one which consists essentially of 20% to 90% sihcified microcrystalline cellulose or cellulose or microcrystalline cellulose, 0% to 20% of low substituted hydroxypropyl cellulose, 0% to 20% crosslinked Polyvinylpyrohdone, a lubricant, a surfactant and an effective amount of a pharmaceutically active agent, wherein said tablet exhibits disintegration within 1 to 15 seconds when tested in an in vitro disintegration test
• the tablet can further comprise flavorants, colorants, or both
• the invention is further directed to the use of a surfactant for making an orally disintegratable non- effervescent pharmaceutical tablet
• a surfactant for making an orally disintegratable non- effervescent pharmaceutical tablet
• the present invention provides also a process of rapidly releasing an active agent from a solid tablet, which comprises disintegrating a tablet as described above, by placing the tablet in a water environment
• the said water environment is an oral cavity or is a waterfilled container
• Insoluble excipients can be either of inorganic origin (like salts e g Calcium Phosphate, Calcium sulfate,
• Suitable disintegrants in this respect are e g swellable polymers, crosslinked swellable polymers, hydrophilic polymers or other substances which take up water and with that increasing their volume
• Pharmaceutically common are Crosscarmellose, crosslinked Polyvinylpyrohdone, L-HPC or Sodium starch glycolate
• Other soluble excipients such as sugars (Lactose, Saccarose, Glusose, Fructose, Maltose) sugar alcohols (Mannitol, Sorbitol, Xyhtol, Eryth ⁇ tol) or soluble actives can be used, as long as their proportion is not to high and their mean particle size remains above 50 ⁇ m
• sugars Limitose, Saccarose, Glusose, Fructose, Maltose
• sugar alcohols Mannitol, Sorbitol, Xyhtol, Eryth ⁇ tol
• soluble actives can be used, as long as their
• soluble actives For the incorporation of soluble actives it was found, that their particle size has an influence on tablet disintegration It is advantageous to have the particles not to small in this case A particle size of greater than 50 ⁇ m (mean value of the distribution) was found to yield the desired tablet properties If solubility of the active(s) is high, or time for dissolution is short, greater mean particle sizes are preferred The way in which the particle size is increased is not important Larger crystals work as good as agglomerates made by granulation (wet- or dry-granulation methods can be used)
• Desired tablet properties are sufficient mechanical stability (expressed as tensile strength and friability), rapid disintegration (expressed as disintegration time using the method described in the European Pharmacopia (European Pharmacopia 5 lh edition 2007 (5 8) Method 2 9 1 , using water at 37°C and the disk), acceptable mouth feeling and taste With the described formulation principle pharmaceutically active substances (drug substances) of different solubility can be formulated.
• Drug substances can either be soluble (like e g the oral Antidiabetics Acarbose or Miglitol) up to insoluble (like e g Nifedipine)
• soluble drug substances a special definition (fraction) of the particle size can be advantageous with respect to disintegration time, content uniformity and tablet hardness
• the particles of the pharmaceutically active substances could be crystals or agglomerates
• the particle size of the pharmaceutically active substances can be 50 ⁇ m-1000 ⁇ m, preferably 100 ⁇ m-800 ⁇ m, more preferably 125 ⁇ m-630 ⁇ m, and most preferably 125 ⁇ m-800 ⁇ m
• the pharmaceutically active substances acarbose, miglitol and voghbose
• the tablets can be obtained by mixing the given components (except for the lubricant Na-stearyl- fumerat) in a suitable mixing device (e g Turbula mixer or tumble blender) for 10 minutes Then add the lubricant and mix for another 5 minutes
• a suitable mixing device e g Turbula mixer or tumble blender
• the Acarbose is premixed with 0,5% (w/w) Na-stearyl-fumerat and compacted
• the compacts are broken and sieved (Dry-granulation or roller-compaction) After sieving the fraction 125 ⁇ m-800 ⁇ m is used
• the tablets disintegrate within 5-10 seconds using the described European Pharmacopia Method

Landscapes

• Health & Medical Sciences (AREA)
• Life Sciences & Earth Sciences (AREA)
• Veterinary Medicine (AREA)
• Animal Behavior & Ethology (AREA)
• Public Health (AREA)
• Medicinal Chemistry (AREA)
• Pharmacology & Pharmacy (AREA)
• Epidemiology (AREA)
• Chemical & Material Sciences (AREA)
• General Health & Medical Sciences (AREA)
• Molecular Biology (AREA)
• Biophysics (AREA)
• Zoology (AREA)
• Nutrition Science (AREA)
• Physiology (AREA)
• Medicinal Preparation (AREA)
• Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Priority Applications (1)

Applications Claiming Priority (3)

Publications (1)

Family

ID=40631079

Family Applications (1)

Country Status (9)

Families Citing this family (25)

Family Cites Families (8)

• 2008
  • 2008-11-25 EP EP08856436A patent/EP2231126A2/de not_active Withdrawn
  • 2008-11-25 BR BRPI0820861-1A patent/BRPI0820861A2/pt not_active IP Right Cessation
  • 2008-11-25 MX MX2010005175A patent/MX2010005175A/es not_active Application Discontinuation
  • 2008-11-25 KR KR1020107012467A patent/KR20100096140A/ko not_active Application Discontinuation
  • 2008-11-25 CN CN2008801194609A patent/CN101888834A/zh active Pending
  • 2008-11-25 WO PCT/EP2008/009968 patent/WO2009071219A2/en active Application Filing
  • 2008-11-25 RU RU2010128019/15A patent/RU2010128019A/ru not_active Application Discontinuation
  • 2008-11-25 JP JP2010536354A patent/JP2011506279A/ja active Pending
  • 2008-12-01 TW TW97146532A patent/TW200938233A/zh unknown
• 2014
  • 2014-10-09 JP JP2014208122A patent/JP2015038123A/ja active Pending

Non-Patent Citations (1)

Also Published As

Similar Documents

Legal Events